Cosunter(SZ:300436) Chang Jiang Shang Bao·2025-08-05 06:00Core Viewpoint - The company Guangshentang (300436.SZ) is gaining significant market attention due to its new hepatitis B drug GST-HG141, which has shown promising results in clinical trials, particularly in suppressing HBVDNA and demonstrating strong antiviral activity [1][2]. Group 1: Drug Development and Clinical Results - The Phase II study results of GST-HG141 were published in the prestigious medical journal eClinicalMedicine, highlighting its innovative mechanism targeting pgRNA and cccDNA, which are crucial for hepatitis B treatment [1]. - The study confirmed the drug's superior efficacy in difficult-to-treat populations compared to existing standard treatments, along with good safety and tolerability [1]. Group 2: Stock Performance - Guangshentang's stock price surged dramatically, increasing from 35.9 CNY per share at the beginning of July to 114.5 CNY per share by July 31, marking a 218.94% increase within one month [2]. - Over the past year, the stock price rose from 14.49 CNY per share to 120.9 CNY per share, reflecting a staggering 734.37% increase [2]. Group 3: Financial Performance - Despite advancements in drug development, the company's financial performance has been disappointing, with revenues of 3.7 million CNY, 3.86 million CNY, 4.23 million CNY, and 4.41 million CNY from 2021 to 2024, respectively [2]. - The company has reported continuous losses over the past four years, totaling 6.67 million CNY, with a net profit loss of 2.848 million CNY in the first quarter of this year [3].